
Mubadala and Novo Holdings are jointly investing €250 million in drug discovery and development firm Evotec
Mubadala and Novo Holdings are jointly investing €250 million in drug discovery and development firm Evotec
Mubadala and Novo Holdings invest €250m in drug discovery firm Evotec
Mubadala will invest €200m to subscribe to 5.6% of Evotec's outstanding shares, while Novo is investing €50m